

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

Alexander C. Ford, MB ChB, MD, FRCP¹, Paul Moayyedi, BSc, MB ChB, PhD, MPH, FAGC, FRCP, FRCPC, AGAF², William D. Chey, MD, FAGC, AGAF, FACP³, Lucinda A. Harris, MD, FAGC⁴, Brian E. Lacy, MD, PhD, FAGC⁵, Yuri A. Saito, MD, MPH, FAGC⁶ and Eamonn M. M. Quigley, MD, MACG, FRCP, FACP, FRCPI⁷ for the ACG Task Force on Management of Irritable Bowel Syndrome

Am J Gastroenterol <https://doi.org/10.1038/s41395-018-0084-x>

INTRODUCTION

Irritable bowel syndrome (IBS) is the most prevalent of the functional gastrointestinal disorders (FGIDs). Current estimates are that IBS affects up to 10–12% of adults in North America [1, 2]. Although it can affect all individuals regardless of age, creed, or gender, IBS is more common among women and is most commonly diagnosed in younger individuals (<age 50) [2, 3]. IBS is characterized by recurrent abdominal pain and altered bowel habits; bloating and distention frequently coexist. The diagnosis of IBS is made by taking a careful history, eliciting key symptoms, as well as performing a physical examination and limited diagnostic testing [4–6]. IBS is categorized into four main subtypes based on the predominant bowel habit: IBS with constipation (IBC-C); IBS with diarrhea (IBS-D); IBS with mixed symptomology (IBS-M); and unclassified IBS [5].

IBS imposes a significant burden to the health care system and to individuals. Direct medical costs attributed to IBS in the US, excluding prescription and over-the-counter medicines, were estimated at \$1.5–\$10 billion per year in 2005 [7]. Patients with IBS enrolled in a large Health Maintenance Organization (HMO) had significantly more outpatient visits and incurred nearly 50% more in total costs than individuals without IBS [8]. A retrospective case-control study from another large HMO reported that patients with IBS had significantly more diagnostic tests, imaging, and surgery compared with patients without a diagnosis of IBS [9]. Significant variations in care across the United States related to the diagnosis and treatment of IBS also play a role in excessive health care costs [10]. The burden of IBS on individuals can be measured in a number of ways. Studies have demonstrated consistently that IBS impairs work-related activities (e.g., lost work time, reduced productivity while at work) and also reduces quality of life [11, 12]. The development of effective and efficient treatment strategies for

IBS assumes considerable importance, therefore, not just for the individual sufferer, but for society at large.

Given the clinical heterogeneity that is a hallmark of the disorder and the absence of a single effective therapy for all sufferers, available therapies tend to focus on predominant symptomatology at presentation (i.e., altered bowel habits, abdominal pain, or bloating) [4–6]. Based on their purported mode of action, many pharmacological therapies for IBS developed in recent decades have been directed towards those with a particular bowel habit, whether diarrhea or constipation. However, treating IBS patients can be difficult as no validated treatment algorithm exists, not all patients respond to treatment, and patients with similar symptoms frequently respond to the same treatment differently. Fortunately, a variety of novel therapeutic strategies are being explored and new compounds have appeared since the last iteration of the ACG monograph on IBS [4]. The goal of this document, therefore, is to provide an updated, evidence-based document on the therapy of this common and, at times, debilitating disorder.

AN OVERVIEW OF METHODOLOGY FOR SYSTEMATIC REVIEWS OF IBS THERAPY

Prior to the last evidence-based systematic review on the management of irritable bowel syndrome commissioned and published by the ACG in 2014 [4], and the work that underpinned this, there had been several systematic reviews of available therapies for IBS [13–22]. We have previously shown that these had either not synthesized the data correctly, or contained inaccuracies in applying eligibility criteria and data extraction [23]. We have, therefore, updated all the rigorously performed meta-analyses [24–27], which informed the ACG position statement in 2014, according to the following protocol:

¹Leeds Institute of Biomedical and Clinical Sciences, University of Leeds and Leeds Gastroenterology Institute, Leeds Teaching Hospitals Trust, Leeds, UK.

²Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada. ³Division of Gastroenterology, Department of Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. ⁴Mayo Clinic, Scottsdale, AZ, USA. ⁵Mayo Clinic, Jacksonville, FL, USA. ⁶Mayo Clinic, Rochester, MN, USA. ⁷Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA. **Correspondence:** E.M.M.Q. (email: equigley@houstonmethodist.org)

Objectives

Primary outcome. To assess the efficacy of available pharmacological therapies in treating IBS compared with placebo, or, in the case of psychological and dietary therapies, in comparison with either no treatment or standard/usual care.

Secondary outcomes. To assess the efficacy of available pharmacological, psychological, and dietary therapies in treating IBS according to predominant stool pattern reported (IBS-C, IBS-D, or IBS-M), and to assess adverse events with pharmacological and other therapies for IBS.

Criteria for considering studies for this review

Types of studies. Only parallel-group randomized controlled trials (RCTs) comparing pharmacological therapies with placebo, or comparing psychological and dietary therapies with either no treatment or standard/usual care, were considered for this review. Cross-over trials were eligible for inclusion, provided extractable data were provided at the end of the first treatment period, prior to cross-over.

Types of participants. Adults over 16 years of age recruited from primary, secondary, or tertiary care with IBS symptoms diagnosed by any criteria (including clinical impression).

Types of interventions. The following treatments were considered eligible:

1. Exercise, diet, and dietary manipulation
2. Fiber
3. Interventions that modify the microbiota: prebiotics, synbiotics, probiotics, and antibiotics
4. Antispasmodics and peppermint oil
5. Antidepressants
6. Psychological interventions
7. Pro-secretory agents: linaclotide, plecanatide, and lubiprostone
8. Eluxadoline
9. Loperamide
10. Serotonergic agents
11. Polyethylene glycol
12. 5-aminosalicylates

Types of outcome measures. Subjects needed to be followed up for at least 1 week. The trials needed to include one or more of the following outcome measures:

1. Global assessment of IBS cure or improvement
2. Abdominal pain cure or improvement
3. Global IBS symptom or abdominal pain scores

Search strategy for identification of studies

MEDLINE (1946 to July 2017), EMBASE and EMBASE Classic (1947 to July 2017), PsychINFO (1806 to July 2017), and the Cochrane central register of controlled trials were searched. The search strategy is given below:

Studies on IBS were identified with the terms *irritable bowel syndrome* and *functional diseases, colon* (both as medical subject

heading (MeSH) and free text terms), and IBS, *spastic colon, irritable colon*, and *functional adj5 bowel* (as free text terms).

For RCTs of dietary manipulation these were combined using the set operator AND with studies identified with the terms: *diet, fat-restricted, diet, protein-restricted, diet, carbohydrate-restricted, diet, gluten-free, diet, macrobiotic, diet, vegetarian, diet, Mediterranean, diet fads, gluten, lactose intolerance, or lactose* (both as MeSH terms and free text terms), or the following free text terms: *FOD-MAPS, glutens, or food adj5 intolerance*.

For RCTs of fiber, antispasmodics, and peppermint oil these were combined using the set operator AND with studies identified with the terms: *dietary fiber, cereals, psyllium, sterculia, karaya gum, parasympatholytics, scopolamine, trimebutine, muscarinic antagonists, or butylscopolammonium bromide* (both as MeSH and free text terms), or the following free text terms: *bulking agent, psyllium fiber, fiber, husk, bran, ispaghula, wheat bran, spasmolytics, spasmolytic agents, antispasmodics, mebeverine, alverine, pinaverium bromide, otilonium bromide, cimetropium bromide, hyoscine butyl bromide, butylscopolamine, drotaverine, peppermint oil, or colpermin*.

For RCTs of prebiotics, synbiotics, probiotics, and antibiotics these were combined using the set operator AND with studies identified with the terms: *Saccharomyces, Lactobacillus, Bifidobacterium, Escherichia coli, probiotics, prebiotics, synbiotics, antibacterial agents, penicillins, cephalosporins, rifamycins, quinolones, nitroimidazoles, tetracycline, doxycycline, amoxicillin, ciprofloxacin, metronidazole, or tinidazole* (both as MeSH and free text terms), or the following free text terms: *antibiotic, or rifaximin*.

For RCTs of antidepressants and psychological therapies, including hypnotherapy, these were combined using the set operator AND with studies identified with the terms: *psychotropic drugs, antidepressive agents, antidepressive agents (tricyclic), desipramine, imipramine, trimipramine, doxepin, dothiepin, nortriptyline, amitriptyline, selective serotonin re-uptake inhibitors, paroxetine, sertraline, fluoxetine, citalopram, venlafaxine, cognitive therapy, psychotherapy, behavior therapy, relaxation techniques, or hypnosis* (both as MeSH terms and free text terms), or the following free text terms: *behavioral therapy, relaxation therapy, or hypnotherapy*.

For RCTs of linaclotide, plecanatide, lubiprostone, eluxadoline, and loperamide these were combined using the set operator AND with studies identified with the terms *loperamide or antidiarrheals* (both as MeSH and free text terms), as well as the following free text terms: *linaclotide, constella, linzess, plecanatide, trulance lubiprostone, amitiza, eluxadoline, viberzi, imodium, or lopex*.

For RCTs of serotonergic agents these were combined using the set operator AND with studies identified with the terms: *serotonin antagonists or receptors (serotonin, 5-HT₃)* (both as MeSH and free text terms), or the following free text terms: *5-HT₃ or alosetron*.

For RCTs of polyethylene glycol these were combined using the set operator AND with studies identified with the term *polyethylene glycol* (both as a MeSH and free text term).

For RCTs of 5-aminosalicylates these were combined using the set operator AND with studies identified with the following terms: *sulfasalazine, mesalamine, or aminosalicylic acid* (both as MeSH terms and free text terms), or the following free text terms: *bal-salazide, olsalazine, mesalazine, pentasa, asulfidine\$, azulfadine\$,*

azulfidine\$, *sulfasalazine*\$, *salazopyrin*\$, *salazosulfapyridine*, 5-ASA, 5ASA, 5-aminosalicylic\$, 5-aminosalicylate\$, 5aminosalicylic\$, or 5aminosalicylate\$.

The search was limited to humans. No restrictions were applied with regard to language of publication. A recursive search of the bibliography of relevant articles was also conducted.

Abstracts. ACG, DDW, and UEGW abstract books between 2000 and 2016 were hand-searched. Authors of trial reports published only as abstracts were contacted and asked to contribute full datasets or completed papers.

Correspondence. Experts in the field were contacted for leads on unpublished studies.

Methods of the review

Selection of studies. The lead reviewer screened titles and trial abstracts that had been identified by the search strategy for articles that could possibly be eligible for the review. The lead reviewer then screened the selected trials to confirm eligibility, using pre-designed eligibility forms. A second reviewer, masked to the initial assessment, also evaluated all identified trials for eligibility. Discrepancies were resolved by discussion and a consensus view was taken.

Assessment of study quality. Only trials that used the word ‘random’, ‘randomly’, or ‘randomized’ in the description of their methodology were considered in this review and assessed for quality according to four characteristics:

- Method used to generate the randomization schedule (truly random or not stated/unclear). Computer generated random numbers, coin toss, or card shuffles, etc. were defined as truly random.
- Method used to conceal treatment allocation (adequate, inadequate, or unclear). If investigators were unaware of each participant’s allocation to a treatment when they were recruited, then the allocation was said to be adequately concealed. Methods such as central randomization systems, or serially numbered opaque envelopes, fit these criteria.
- Implementation of masking (patients masked, clinicians masked, outcome assessors masked). When an identical placebo was used it was assumed that the participants were masked to their treatment allocation.
- Completeness of follow-up and intention-to-treat analysis. Wherever possible, completeness of follow-up and intention-to-treat analysis was recorded, as were dropout rates by group. Study quality was assessed by one reviewer and checked by a second.

Data extraction. All data were extracted independently by two investigators on to a Microsoft Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA). Any disagreement between investigators was resolved by discussion. The following characteristics were recorded for each trial:

- Setting: population-based, primary care, secondary care, tertiary care
- Country of origin and number of centers involved
- Dose of therapy
- Duration of therapy
- Adverse events: both total number and individual adverse events, if available
- Definition of IBS used
- Primary outcome measure used

Data were extracted as intention-to-treat analyses, with all drop-outs assumed to be treatment failures, wherever trial reporting allowed this.

Data synthesis and analysis. For binary outcomes, (global IBS symptoms or abdominal pain improved or cured), the impact of interventions were expressed as relative risks (RR) of global IBS symptoms or abdominal pain not improving, together with 95% confidence intervals (CIs). Data were pooled using a random effects model, in order to give a more conservative estimate of the efficacy of individual IBS therapies [28]. The number needed to treat (NNT) for treatment efficacy, and the number needed to harm (NNH) for adverse events, were calculated using the formula $NNT \text{ or } NNH = 1/(\text{control event rate} \times (1-RR))$. These provide useful summary estimates for efficacy and safety for each of the active interventions of interest over a placebo or control intervention, corresponding to the number of extra patients needing to be treated with the active intervention over and above placebo or the control intervention to see one of the events of interest (i.e., a patient experiencing an improvement of symptoms or an adverse event). However, it should be pointed out that these cannot be used to compare the relative efficacy of one active intervention versus another, as they are not based on head-to-head studies. In addition, for NNHs, which are derived from summaries of adverse events it is important to point out that the definitions of these adverse events are also not standardized between individual trials, so again should not be compared. For continuous data, such as global IBS symptom scores or individual IBS symptom scores, a standardized mean difference (SMD), with 95% CIs, was calculated.

The results of individual studies can be diverse, and this inconsistency within a single meta-analysis can be quantified with a statistical test of heterogeneity, to assess whether the variation across trials is due to true heterogeneity, or chance. This quantity is termed *I*², and its value ranges from 0 to 100%, with 0% representing no observed heterogeneity, and larger values indicating increasing heterogeneity. A value $\leq 50\%$, accompanied by a *P* value of >0.10 for the χ^2 test, was arbitrarily chosen to represent low levels of heterogeneity [29].

Review Manager version 5.3.5 (RevMan for Windows 2014, The Nordic Cochrane Centre, Copenhagen, Denmark) was used to generate Forest plots of pooled RRs and SMDs for primary and secondary outcomes with 95% CIs, as well as funnel plots. The latter were assessed for evidence of asymmetry, and therefore possible publication bias or other small study effects, using the Egger test [30], if there were sufficient (10 or more) eligible studies included in the meta-analysis, in line with published recommendations [31]. GRADEpro version 3.6 (GRADE working group 2004–2007)

was used to grade the quality of the evidence. Consensus was reached using a consensus-oriented decision-making framework [32], culminating in a face-to-face meeting to discuss the evidence and reach a unanimous decision on the quality of evidence and strength of recommendation.

EXERCISE, DIET AND DIETARY MANIPULATION

Exercise

We suggest exercise for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of Evidence: very low)

Exercise and physical fitness are key elements of maintaining physical and mental health [33, 34]. Studies from healthy volunteers and patients suggest that physical activity protects against gastrointestinal (GI) symptoms [35, 36], and bears an inverse relationship with colonic transit time [37].

Based upon these observations, it is reasonable to hypothesize that exercise might be beneficial to patients with IBS. To date, there have been few RCTs that have rigorously evaluated the benefits of exercise in IBS patients. Daley et al. invited 305 IBS patients to participate in a RCT that compared 12 weeks of an exercise intervention with usual care [38]. Fifty-six IBS patients (18%) agreed to participate. Quality of life (IBS-QOL) and IBS symptoms (Birmingham IBS symptoms questionnaire) were assessed before and after the interventions. Exercise led to statistically significant benefits for constipation (95% CI: -1.6 to -20.1) but not for other outcomes such as abdominal pain, diarrhea, total symptom score, or quality of life.

In a second trial, Johannesson et al. randomized 102 IBS patients to a rigorous exercise program monitored by a physiotherapist or usual care for 12 weeks [39]. Seventy-five IBS patients completed the trial. IBS symptom severity scores improved to a greater degree in the exercise arm compared with the control arm ($P=0.003$). The same authors reported long-term follow-up data (median follow-up 5.2 years) for 39 of the originally enrolled IBS patients [40]. Increases in physical activity and improvements in symptom scores compared with baseline were maintained at follow-up.

Summary. Although it is clear that exercise offers general health benefits and, whenever possible, should be encouraged the Task Force did not feel that the weight or strength of available evidence justified a strong recommendation regarding exercise for IBS. Although encouraging, the Task Force feels that the current body of evidence should be viewed as hypothesis-generating, and in need of validation by methodologically rigorous, appropriately powered, RCTs.

Diet and dietary manipulation for IBS

We suggest a low FODMAP diet for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: very low)

We suggest against a gluten-free or exclusion diet based upon antibody or leukocyte activation test for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: very low)

The majority of IBS patients associate symptom onset or worsening with eating a meal. Although true food allergy is uncommon in IBS patients, perceived food intolerances or sensitivities are quite common. Up to 90% of IBS patients exclude certain foods in the hopes of avoiding or improving their GI symptoms [41].

Since the publication of the last IBS Task Force evidence-based review in 2014 [4], there have been numerous studies that have evaluated dietary therapies in IBS patients [42]. Although various diets have been suggested to benefit IBS patients, the largest body of evidence relates to two specific diets; a diet low in fermentable oligo-saccharides, di-saccharides, and mono-saccharides, and polyols (FODMAPs) and a gluten-free diet.

We identified seven eligible RCTs (evaluating 397 participants) that provided dichotomous outcomes for a low FODMAP diet versus an alternative diet [43–49]. There was an overall effect of the low FODMAP diet in reducing IBS symptoms with a RR of remaining symptomatic on a low FODMAP diet of 0.69 (95% CI 0.54 to 0.88). The NNT was 5 (95% CI 3 to 11) (Table 1).

Similar to another recent systematic review [50], our analysis found that all trials were subject to high risk of bias. Overall, the quality of the evidence was graded as very low, which related to imprecision resulting from the relatively small number of patients included in the trials, significant heterogeneity, and issues around blinding.

Three trials in 271 IBS patients compared the low FODMAP diet with an alternative diet [43, 44, 47], two with usual diet [46, 48], and one with a high FODMAP diet [45]. The three trials that had adequate concealment of allocation and an alternative dietary intervention in the control arm showed no statistically significant benefit of a low FODMAP diet (RR = 0.82; 95% CI = 0.66 to 1.02) with no heterogeneity between studies [43, 44, 47]. The results of these trials are more difficult to interpret as they were not placebo-controlled, but rather, comparative effectiveness trials assessing two active dietary interventions. In each of these RCTs, the low FODMAP diet led to adequate relief of IBS symptoms in roughly half of the patients.

None of the RCTs have evaluated the long-term efficacy of, or adherence to, a low FODMAP diet, or the personalized maintenance diet that is instituted after individual FODMAP reintroduction. Potential harms, which should be balanced with benefit, include impact on quality of life (e.g., social encounters) and effects on the colonic microbiome, which could exert negative effects on colonic health [45, 51–53].

We identified two eligible trials evaluating a gluten-free diet in 111 patients with IBS [54, 55]. Both were re-challenge trials involving IBS patients that reported that their symptoms were controlled with a gluten-free diet, but in whom celiac disease had been rigorously excluded. Participants were then randomized to have this diet spiked with gluten or not. This design only indirectly addresses the research question, as withdrawing a significant food group from the diet and then introducing it may enhance the likelihood of a placebo response. There was no statistically significant impact on IBS symptoms in the gluten challenge versus gluten-free diet (RR = 0.46; 95% CI 0.16 to 1.28) with significant heterogeneity between studies ($I^2 = 86\%$, $P = 0.008$) (Table 1).

Table 1 Summary of evidence from randomized controlled trials of pharmacological, psychological, and dietary therapies in irritable bowel syndrome

Intervention	Number of RCTs	Number of patients	IBS subtype	Relative risk of re-remaining symptomatic vs. placebo (95% CI)	Heterogeneity (<i>I</i> ² value)	Number needed to treat (95% CI)	Recommendation and Strength of Evidence
Exercise	2	158	Not stated	No dichotomous data reported	No dichotomous data reported	No dichotomous data reported	Weak, very low
Low FODMAP diet	7	397	Not stated	0.69 (0.54 to 0.88)	52%	5 (3 to 11)	Weak, very low
Gluten-free diet	2	111	Not stated	0.46 (0.16 to 1.28)	86%	N/A	Weak, very low
Fiber	15	946	Not stated	0.87 (0.80 to 0.94)	0%	11 (7 to 25)	Strong, moderate
Insoluble fiber e.g., bran	6	441	Not stated	0.90 (0.79 to 1.03)	0%	N/A	
Soluble fiber e.g., psyllium	7	499	Not stated	0.83 (0.73 to 0.94)	18%	7 (4 to 25)	
Prebiotics	1	128	IBS-D	No dichotomous data reported	No dichotomous data reported	No dichotomous data reported	Weak, very low
Synbiotics	2	198	Not stated	Only one RCT reported dichotomous data	Only one RCT reported dichotomous data	Only one RCT reported dichotomous data	Weak, very low
Probiotics	37	4403	Not stated	0.81 (0.74 to 0.88)	71%	7 (5 to 12)	Weak, low
Antibiotics (rifaximin)	6	2441	IBS-D or IBS-M	0.86 (0.81 to 0.91)	0%	10.5 (8 to 16)	Weak, moderate
Antispasmodics	26	2811	Not stated	0.65 (0.56 to 0.76)	69%	5 (4 to 8)	Weak, very low
Peppermint oil	7	634	Not stated	0.54 (0.39 to 0.76)	73%	4 (3 to 6)	Weak, low
Antidepressants	18	1127	Not stated	0.66 (0.57 to 0.76)	37%	4 (3.5 to 6)	
Tricyclic antidepressants	12	787	Not stated	0.65 (0.55 to 0.77)	34%	4 (3.5 to 7)	Strong, high
Selective serotonin re-uptake inhibitors	7	356	Not stated	0.68 (0.51 to 0.91)	49%	5 (3 to 16.5)	Weak, low
Psychological therapies	36	2487	Not stated	0.69 (0.62 to 0.76)	69%	4 (3.5 to 5.5)	Weak, very low
Linacotide	4	2867	IBS-C	0.81 (0.77 to 0.85)	0%	6 (5 to 8)	Strong, high
Plecanatide	3	2612	IBS-C	0.88 (0.84 to 0.92)	0%	10 (8 to 14)	Strong, moderate
Lubiprostone	3	1366	IBS-C	0.91 (0.87 to 0.95)	0%	12.5 (8 to 25)	Strong, moderate
Eluxadoline	3	3235	IBS-D	0.91 (0.85 to 0.97)	66%	12.5 (8 to 33)	Weak, moderate
Loperamide	2	42	IBS-D or IBS-M	0.44 (0.14 to 1.42)	54%	N/A	Strong, very low
Alosetron	8	4987	IBS-D	0.79 (0.69 to 0.90)	85%	7.5 (5 to 16)	Weak, low
Polyethylene glycol	2	181	IBS-C	No dichotomous data reported	No dichotomous data reported	No dichotomous data reported	Weak, low
5-aminosalicylates (mesalamine)	3	464	IBS-D in two RCTs	0.85 (0.75 to 0.97)	0%	9 (5 to 50)	Weak, low

Another RCT evaluated 150 patients with IBS randomized to exclude all foods for which they had abnormal levels of IgG antibodies, or a sham diet where patients were asked to avoid a similar number of foods, but this was not based upon the IgG antibody test results [56]. This trial had an unclear risk of bias. Participants were followed for 12 weeks and 18 (28%) of 65 in the active intervention arm noted a significant improvement in symptoms, compared with 11 (17%) of 66 in the sham diet arm. This difference in response rates was not statistically significant ($P=0.14$). The authors reported marginal statistical significance in those that adhered to their diet.

A more recent RCT utilized leukocyte activation testing to evaluate a true vs. sham elimination diet in 58 IBS patients [57]. This study reported no difference in the proportion of patients with adequate relief of their IBS symptoms ($P=0.31$) or quality of life ($P=0.92$) after 4 weeks (secondary endpoints). However, there was a significantly greater increase in IBS global improvement scale score (primary endpoint) with the true vs. sham elimination diet ($P=0.04$) after 4 weeks.

Summary. Dietary therapies for IBS are of growing interest to patients, providers, and investigators. At present, the largest body of literature pertains to the low FODMAP diet. The available evidence

supports a possible benefit for overall IBS symptoms in roughly half of sufferers. There are much less data for a gluten-free diet or elimination diets based upon IgG antibody or leukocyte activation testing. Importantly, there are little or no data that address the long-term efficacy, adherence, or harms of dietary therapies for IBS.

FIBER IN IBS

We recommend fiber for overall symptom improvement in IBS patients. (Recommendation: strong; Quality of evidence: moderate)

We recommend psyllium, but not wheat bran, for overall symptom improvement in IBS patients. (Recommendation: strong; Quality of evidence: moderate)

The updated systematic review and meta-analysis on fiber in IBS performed for this guideline identified 15 RCTs, involving 946 patients [58–72]. Only one trial was at low risk of bias [70].

There was a statistically significant effect in favor of fiber compared with placebo (RR of IBS not improving = 0.87; 95% CI 0.80 to 0.94) (Table 1). There was no significant heterogeneity between results ($I^2=0\%$, $P=0.53$). Six studies used bran in a total of 411 patients [58, 59, 64, 65, 69, 70], seven studies ispaghula husk in a total of 499 patients [60–63, 66, 67, 70], and the remaining three studies used “concentrated fiber” [68], linseeds [71], or rice bran [72]. Bran had no significant effect on treatment of IBS (RR of IBS not improving = 0.90; 95% CI 0.79 to 1.03), but ispaghula was effective in treating IBS (RR = 0.83; 95% CI 0.73 to 0.94). The NNT with ispaghula was 7 (95% CI 4 to 25).

Data on overall adverse events were only provided by seven trials [63, 64, 66, 68, 70–72]. These trials evaluated 606 patients. A total of 130 (36.6%) of 355 patients receiving fiber reported adverse events, compared with 63 (25.1%) of 251 in the placebo arms (RR = 1.06; 95% CI 0.92 to 1.22). There were insufficient data from individual studies to assess adverse events according to type of fiber administered.

Summary. Poorly fermentable, soluble fiber remains an evidence-based treatment for IBS. Insoluble fiber may exacerbate pain and bloating in IBS, and has no evidence for efficacy. The low cost and lack of significant side effects makes soluble fiber a reasonable first-line therapy for IBS patients and, in combination with the moderate quality of evidence, is the basis of a strong recommendation. The ability to improve stool viscosity and frequency logically argues for the use of fiber in patients with IBS-C, although the evidence base to support this contention is far from conclusive.

INTERVENTIONS THAT MODIFY THE MICROBIOTA: PREBIOTICS, SYNBIOTICS, PROBIOTICS AND ANTIBIOTICS

Prebiotics and synbiotics

We suggest against the use of prebiotics and synbiotics for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: very low)

The concept that alterations in the gut microbiome might be relevant to IBS arose from observations that symptoms of IBS developed after an infection (post-infectious IBS) [73], that small intestinal bacterial overgrowth (SIBO) may cause symptoms indistinguishable from IBS [74], and that the colonic microbiota is altered in IBS [75, 76]. In addition, some IBS symptoms (e.g., bloating, slowed intestinal transit, and early satiety) have been associated with specific gut microbiota profiles [77, 78].

These observations have also led to the use of prebiotics, probiotics, and synbiotics, as well as antibiotics, in the treatment of IBS. Prebiotics are food or dietary supplements that result in specific changes in the composition and/or activity of the GI microbiota. Probiotics have been defined as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” [79]. Synbiotics, which are also food or dietary supplements, are a mixture of probiotics and prebiotics that act synergistically to promote the growth and survival of beneficial organisms.

The previous monograph identified no trials of prebiotics in IBS [4]. The updated search identified one RCT [80]. In this study 128 patients with IBS-D were recruited, and randomized to receive either prebiotics (derived from chicory) or placebo for 8 weeks. This double-blind trial was at unclear risk of bias due to failure to report the method used to conceal treatment allocation. Neither global IBS symptoms nor abdominal pain were reported as a dichotomous outcome by the investigators. Mean abdominal pain relief scores at 8 weeks were significantly higher with the prebiotic vs. the placebo (4.92 ± 0.86 vs. 3.13 ± 1.36 , $P < 0.001$). Flatulence scores were also significantly improved with prebiotic (4.97 vs. 2.98 , $P = 0.037$). Data on adverse events were incompletely reported.

With regard to synbiotics, no new RCTs were identified since the last version of the monograph [4], but there were two studies that recruited a total of 198 patients [81, 82]. The first was a single-blind RCT conducted in Italy [81], recruiting 68 patients with IBS, and which used a combination of *Lactobacillus acidophilus* and *helveticus*, with *Bifidobacterium* species, in a vitamin and phytoextract-enriched medium for 12 weeks. Only this trial reported dichotomous data. There were 7 (20.6%) of 34 patients assigned to synbiotics with persistent symptoms, compared with 30 (88.2%) of 34 assigned to control therapy ($P < 0.01$). The second study, conducted in South Korea [82], used *Bifidobacterium lactis* in combination with acacia fiber for 8 weeks in 130 patients. This double-blind trial was at unclear risk of bias due to failure to report the method used to conceal treatment allocation. Both trials assessed IBS symptoms on a continuous scale in 185 patients. Even though both trials were individually positive, there was no statistically significant effect of synbiotics in reducing symptoms, due to significant heterogeneity between studies (SMD = -1.73 ; 95% CI -3.73 to 0.27 , $I^2 = 96\%$, $P = 0.09$). In both synbiotic studies adverse events were reported, and no significant events occurred in either treatment arm.

Probiotics

We suggest probiotics, taken as a group, to improve global symptoms, as well as bloating and flatulence in IBS patients. (Recommendation: weak; Quality of evidence: low)

Since the previous monograph a total of 18 new trials were identified [47, 83–99]. Therefore, in total, there were 53 RCTs [47, 83–134], involving 5545 patients. Twenty-six trials were at low risk of bias, [47, 83, 84, 87–90, 92, 93, 96, 98, 99, 103, 105, 110, 112, 114, 115, 119, 121, 123, 124, 126, 130, 132, 133] with the remainder being unclear. There were 37 RCTs involving 4403 patients that gave outcomes as a dichotomous variable [47, 84, 86–89, 91, 92, 94–104, 110, 112, 113, 115, 118, 119, 121, 123, 125–134].

Probiotics were statistically superior to placebo (RR of IBS not improving = 0.81; 95% CI 0.74 to 0.88), with a NNT of 7 (95% CI 5 to 12) (Table 1). However, there was significant heterogeneity between studies ($I^2 = 71%$, $P < 0.001$), and evidence of funnel plot asymmetry or other small study effects (Egger test, $P = 0.06$). Combination probiotics were assessed in 21 RCTs, containing 1931 patients, with a benefit of probiotics compared with placebo (RR = 0.79; 95% CI 0.68 to 0.91), but with significant heterogeneity between studies ($I^2 = 72%$, $P < 0.001$), and there was evidence of publication bias or other small study effects (Egger test, $P = 0.06$).

Probiotics appeared to have beneficial effects on global IBS symptom scores or abdominal pain scores (SMD = -0.21; 95% CI -0.31 to -0.10), bloating scores, (SMD = -0.13; 95% CI -0.24 to -0.02), and flatulence scores (SMD = -0.23; 95% CI -0.38 to -0.08), although with significant heterogeneity in some of these analyses.

Total adverse events were reported by 36 RCTs [85–87, 89–93, 95–97, 99–106, 111, 113–116, 118–124, 127, 129, 130, 132, 133], containing 4183 patients. The RR of experiencing any adverse event was not significantly higher with probiotics (1.09; 95% CI 0.91 to 1.29).

Antibiotics

We suggest the non-absorbable antibiotic rifaximin for reduction in global IBS symptoms, as well as bloating in non-constipated IBS patients. (Recommendation: weak; Quality of evidence: moderate)

We identified three additional RCTs of antibiotics in IBS [135–137] since the previous monograph [4], meaning there were a total of 9 RCTs reported in 8 papers [135–142]. These trials involved 2845 participants. Overall, antibiotic therapy improved IBS symptoms compared with placebo (RR of symptoms not improving = 0.79; 95% CI 0.70 to 0.90), but with statistically significant heterogeneity between studies ($I^2 = 75%$, $P < 0.001$). The NNT was 7 (95% CI 5 to 14.5).

Six RCTs used the minimally absorbed antibiotic rifaximin [137, 139–142], in patients representative of usual clinical practice, recruiting 2441 non-constipated IBS patients (predominantly IBS-D). Overall, there was a statistically significant benefit in favor of the antibiotic (RR = 0.86; 95% CI 0.81 to 0.91) with no significant heterogeneity noted between the studies ($I^2 = 0%$, $P = 0.71$) (Table 1). The NNT was 10.5 (95% CI 8 to 16). There was a seventh trial [136], recruiting 213 patients with IBS who also had lactose intolerance and bacterial overgrowth on breath testing. When this trial was included rifaximin remained an effective treatment (RR = 0.82; 95% CI 0.72 to 0.95), but with significant heterogeneity between studies ($I^2 = 77%$, $P < 0.001$). The NNT was 8 (95% CI 5

to 29). There were four rifaximin RCTs at low risk of bias, assessing 1966 patients [137, 139, 142], and pooled data from these four trial suggested rifaximin was superior to placebo in terms of improving IBS symptoms (NNT = 11; 95% CI = 8 to 21). The quality of evidence was considered moderate due to the modest impact on IBS symptoms and heterogeneity between studies. A pooled analysis revealed no difference in adverse events (52% in both rifaximin and placebo arms) or serious adverse events (approximately 2% in each arm) between rifaximin and placebo [143].

There has been concern with antibiotic therapies for IBS due to the risk of developing *Clostridium difficile* infection. A pooled analysis of the phase 2b study and two of the phase 3 studies found *C. difficile* in one patient at study entry who subsequently was removed from the study [143]. There was a zero incidence of *C. difficile* colitis that developed de novo. In the TARGET 3 trial, a further case of *C. difficile* colitis was reported among the 328 patients randomized to re-treatment with rifaximin [137].

In an effort to understand the mechanism of action of rifaximin, there have been additional concerns about the impact of this drug on the gut microbiota. Studies have revealed that a 2-week course of treatment causes modest, but detectable, changes in microbial profiles of the feces [144, 145]. Other research studies evaluating fecal microbial profiles from IBS patients demonstrated that rifaximin effects on the microbiota were limited and not sustained [145–147].

Summary. Despite the fact that patients and clinicians may use or recommend prebiotics or synbiotics, there are few data to support their use. Although overall there was a benefit of probiotics the evidence was low quality and hence they receive a weak recommendation. Variations in study design, IBS subtype recruited, type and dose of probiotic, as well as the small size of some of the study populations, and a lack of comparative studies, preclude a recommendation on use of a particular species or strain for the treatment of IBS, or the subtype most likely to respond. Although rifaximin treatment appears to be beneficial in IBS, its efficacy is modest. The modest efficacy is why the Task Force gave a weak recommendation, despite the moderate quality data. Although data from preliminary studies concerning rates of *C. difficile* infection and microbial resistance are reassuring [143, 144, 148], future research should continue to examine these outcomes, particularly in patients receiving repeated courses of rifaximin. Advances in molecular techniques may provide further insight into the fecal microbiota of IBS patients compared with healthy controls, which may in turn improve the understanding of the role of antibiotic therapy, and its place in the treatment of this complex disorder.

ANTISPASMODICS AND PEPPERMINT OIL IN IBS

Antispasmodics

We suggest certain antispasmodics (otilonium, pinaverium, hyoscine, cimetropium, drotaverine, and dicyclomine) for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: very low)

We identified three additional studies evaluating antispasmodics since the previous monograph [149–151]. We therefore included 26 RCTs [60, 63, 64, 149–171], evaluating 2811 patients with IBS.

Risk of bias was low in two of the trials [149, 150]. Antispasmodic therapy had a statistically significant effect in improving IBS symptoms (RR of IBS symptoms not improving = 0.65; 95% CI 0.56 to 0.76). The NNT was 5 (95% CI 4 to 8) (Table 1). There was statistically significant heterogeneity ($I^2 = 69\%$, $P < 0.001$) and there were 13 different antispasmodics evaluated. There was also funnel plot asymmetry (Egger test, $P = 0.035$), which may indicate publication bias or other small study effects, although this was difficult to interpret with so many different antispasmodics being studied.

The effect of individual antispasmodics was also difficult to interpret as there were only a small number of studies evaluating each drug. Otilonium was studied in five RCTs, including 791 patients [162, 163, 168, 169, 171], with a beneficial effect (RR = 0.70; 95% CI 0.54 to 0.90), and a NNT of 5 (95% CI 4 to 11), but borderline heterogeneity between study results ($I^2 = 44\%$, $P = 0.13$). Pinaverium bromide was studied in four trials [150, 156–158], assessing 615 patients, and there was a statistically significant effect on improving IBS symptoms (RR = 0.56; 95% CI 0.38 to 0.82) with a NNT of 4 (95% CI 3 to 6). There was statistically significant heterogeneity ($I^2 = 61\%$, $P = 0.05$). Hyoscine bromide was studied in three RCTs [60, 63, 152], assessing 426 patients, and there was a statistically significant effect on improving IBS symptoms (RR = 0.63; 95% CI 0.51 to 0.78) with a NNT of 3 (95% CI 2 to 25). There was no statistically significant heterogeneity in the results ($I^2 = 0\%$, $P = 0.62$). Cimetropium bromide was studied in three trials [153–155], assessing 158 patients, and there was a statistically significant effect on improving IBS symptoms (RR = 0.38; 95% CI 0.20 to 0.71) with a NNT of 3 (95% CI 2 to 12.5). There was no statistically significant heterogeneity in the results ($I^2 = 37\%$, $P = 0.20$). Drotaverine was studied in two RCTs [149, 151], containing 150 patients, and was more effective than placebo (RR = 0.31; 95% CI 0.19 to 0.50, NNT = 2 (95% CI 2 to 3), $I^2 = 29\%$, $P = 0.24$). Finally, dicyclomine hydrochloride was studied in one trial [167], assessing 97 patients and there was a statistically significant effect on improving IBS symptoms (RR of IBS not improving = 0.65; 95% CI 0.45 to 0.95) with a NNT of 4 (95% CI 2 to 25). Mebeverine (one trial), trimebutine (three trials), pirenzepine (one trial), alverine (one trial), rociverine (one trial), prifinium (one trial), and propinox (one trial) did not have a statistically significant effect on IBS symptoms, although the number of patients studied were small.

Seventeen trials reported adverse events with either active drug or placebo [64, 149–156, 159–161, 163, 165, 167, 168, 171]. When data were pooled the incidence of adverse events was significantly higher among those taking antispasmodics, compared with placebo (RR = 1.60; 95% CI 1.15 to 2.21), with a NNH of 22 (95% CI 12 to 200). The commonest adverse events were dry mouth, dizziness, and blurred vision, but there were no serious adverse events reported in either treatment arm in any of the trials.

Peppermint oil

We suggest peppermint oil for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: low)

We identified two additional studies of peppermint oil since the previous monograph [172, 173]. There were therefore seven RCTs [172–178], involving 634 patients. In one of these, there were no

dichotomous data reported, but we contacted the authors and successfully obtained these [172]. There were only two RCTs at low risk of bias [172, 178]. There was a statistically significant effect in favor of peppermint oil compared with placebo (RR = 0.54; 95% CI 0.39 to 0.76). The NNT with peppermint oil was 4 (95% CI 3 to 6) (Table 1). However, there was significant heterogeneity between results ($I^2 = 73\%$, $P = 0.001$). There were too few studies to assess for any evidence of funnel plot asymmetry.

Data on overall adverse events were provided by six trials [172, 173, 175–178]. When data were pooled, the incidence of adverse events was not significantly higher among those taking peppermint oil, compared with placebo (RR = 1.90; 95% CI 0.81 to 4.48). **Summary.** Although anti-spasmodics have been a mainstay of IBS management for decades, based on the assumption that dysmotility or “spasm” may be fundamental to the pathogenesis of IBS symptoms, and of pain in particular [179], the evidence base to support their use remains modest. Most studies involving anti-spasmodics in IBS are small in size and were performed long before current standards for the definition of [5], and conduct of clinical trials in [180], FGIDs were developed. Nevertheless, antispasmodics, as a category, do appear to exert short-term benefits in IBS.

Our analysis suggests a benefit for peppermint oil in IBS, but this recommendation is based on a small number of clinical trials involving very specific formulations. Their findings should not be extrapolated to the many other products available through a variety of sources that have not been subjected to study. Although, overall, adverse events appeared to be no more common with peppermint oil than placebo, heartburn has been reported [181], presumably related to its effect as a relaxant of esophageal muscle. This could be an issue in an IBS subject, given the frequent occurrence of this symptom in the IBS sufferer [182], but may be avoided by the use of enteric coated preparations that provide more distal delivery.

ANTIDEPRESSANTS FOR THE TREATMENT OF IBS

We recommend TCAs for overall symptom improvement in IBS patients. (Recommendation: strong; Quality of evidence: high)

We suggest SSRIs for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: low)

Similar to other FGIDS, symptoms of IBS may arise as a manifestation of a brain-gut disorder [5, 6]. Abnormalities in brain-gut function include disorders of sensory processing, leading to both visceral and central hypersensitivity [183]. The high prevalence of overlapping psychological disorders in IBS patients, including anxiety, depression, and somatization [184, 185], has encouraged many providers to use centrally acting therapies, including neuromodulators and psychological therapies. The two classes of central neuromodulators most commonly used to treat FGIDs are tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), as well as their effects on central pain and psychological distress, TCAs and SSRIs may also impact on bowel function, with TCAs improving diarrhea by slowing GI transit, and SSRIs ameliorating constipation by accelerating GI transit [186, 187].

We updated the previous version of the monograph [4], and identified one further paper [188]. Overall, the search strategy identified a total of 18 RCTs [63, 188–204], evaluating 1127 patients. Only four of the RCTs were at low risk of bias [188, 194, 203, 204], with the remainder being unclear.

As a group, antidepressants (both TCAs and SSRIs) were found to be effective for treating IBS symptoms (RR of symptoms not improving with antidepressants = 0.66; 95% CI 0.57 to 0.76) (Table 1). Not unexpectedly, given differences in study design, heterogeneity was identified in these results, although this was of borderline statistical significance ($I^2 = 37\%$; $P = 0.06$). A funnel plot analysis showed statistically significant asymmetry (Egger test, $P = 0.03$) suggesting possible publication bias or the influence of other small study effects. This asymmetry appeared to be overly influenced by the TCA arm of one small study [200]; when this was removed from the analysis the asymmetry resolved. The NNT was 4 (95% CI 3.5 to 6). Seven RCTs reported effects of antidepressants on abdominal pain [189, 193, 195–198, 204]. The RR of abdominal pain persisting was 0.62 (95% CI 0.43 to 0.88). However, significant heterogeneity was noted between studies ($I^2 = 72\%$, $P = 0.001$).

TCAs were studied in 12 RCTs involving a total of 787 patients [63, 188–194, 197, 200, 201, 204]. Patients treated with a TCA were more likely to report an improvement in IBS symptoms compared with those treated with placebo (RR = 0.65; 95% CI 0.55 to 0.77). No significant heterogeneity was noted between the studies ($I^2 = 34\%$; $P = 0.12$). The NNT with TCAs was 4 (95% CI 3.5 to 7). Only three RCTs were low risk of bias [188, 194, 204], but when only these studies were included in the analysis the beneficial effect of TCAs in IBS remained (RR = 0.58; 95% CI 0.36 to 0.94, NNT = 5; 95% CI 2 to 24).

SSRIs were studied in seven RCTs involving a total of 356 patients [195, 196, 198–200, 202, 203]. Patients treated with an SSRI were more likely to note a reduction in IBS symptoms compared with those treated with placebo (RR = 0.68; 95% CI 0.51 to 0.91). Significant heterogeneity was identified between individual trials ($I^2 = 49\%$; $P = 0.07$). The NNT with SSRIs was 5 (95% CI 3 to 16.5).

Some of the strongest evidence for the pain-modifying effects of antidepressants in chronic painful disorders comes from high quality RCTs of the serotonin and norepinephrine re-uptake inhibitors (SNRIs) duloxetine and milnacipran, [205–209] neither of which have been tested in IBS trials to date. However, one open-label trial of duloxetine, which involved 13 patients with IBS and a generalized anxiety disorder, had encouraging results [210].

Overall adverse events, comparing either a TCA or SSRI to placebo, were reported in eight studies [188–191, 193, 195, 199, 201]. The incidence of adverse events was higher in patients treated with an antidepressant compared with those treated with placebo (RR = 1.56; 95% CI 1.23 to 1.98). The NNH was 8.5 (95% CI 5 to 21). The most common adverse events reported in those taking a TCA were drowsiness and dry mouth.

Summary. Both TCAs and SSRIs are effective in relieving pain and overall symptoms in IBS. These agents have both central and peripheral effects; their relative importance to efficacy in IBS is unclear. Whether all IBS sufferers, or only certain sub-populations,

respond to anti-depressants is also unclear, and therapy with these agents may be limited by patient acceptance and adverse events, such as dry mouth.

PSYCHOLOGICAL THERAPIES

We suggest some psychological therapies (provider-directed cognitive behavioral therapy, relaxation therapy, hypnotherapy, and multicomponent psychological therapy) for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: very low)

There were a total of 34 articles [194, 211–243], reporting on 36 separate RCTs, comparing various psychological therapies with control therapy in the form of symptom monitoring, physician's "usual management", supportive therapy, or placebo for the treatment of IBS in a total of 2487 patients. Four of these were identified since the previous monograph. [234, 238, 242, 243] None of the trials were considered to be at low risk of bias.

IBS patients treated with psychological therapies were more likely to improve than patients not treated with psychological intervention (RR = 0.69; 95% CI 0.62 to 0.76). The NNT was 4 (95% CI 3.5 to 5.5) (Table 1). However, there was significant heterogeneity between the studies ($I^2 = 69\%$, $P < 0.001$), and funnel plot analysis demonstrated asymmetry (Egger test, $P < 0.001$), suggesting possible publication bias. Cognitive behavioral therapy, relaxation therapy, multi-component psychological therapy, hypnotherapy, and dynamic psychotherapy were all more effective than control therapy, when data from two or more RCTs were pooled, with NNTs of between 4 and 6. Multi-component psychological therapy delivered mainly via the telephone, contingency management, and emotional awareness and expression training also appeared beneficial, although there was only one RCT for each of these treatment modalities. Finally, adverse events data were poorly reported among trials.

Summary. Various psychological therapies appear to be effective in IBS but the interpretation of many studies is hampered by the absence of a true sham control which is, admittedly, difficult to construct for these particular interventions. Some benefits may also be therapist-dependent, and may not be reproducible when performed by a non-expert. These therapies may not be widely available and can be time consuming for the patient and the therapist; it is possible that, in the future, electronic technologies may improve access. They appear to be safe, although few RCTs report adverse events.

PROSECRETORY AGENTS

Linaclotide

We recommend linaclotide for overall symptom improvement in IBS-C patients. (Recommendation: strong; Quality of evidence: high)

Linaclotide is a 14-amino acid peptide, which is structurally related to human guanylin and uroguanylin. It is a truncated homolog of heat-stable enterotoxins (ST) from *E. coli*, which are natural ligands to the guanylate cyclase-C (GC-C) receptor, and its three disulfide bonds engender a high affinity for this receptor,

irrespective of pH. Once bound to the GC-C receptor the drug activates the cystic fibrosis transmembrane regulator, resulting in luminal chloride, bicarbonate, and water secretion. There is also evidence from animal studies that activation of GC-C leads to cyclic GMP release, which inhibits nociceptors, leading to improvements in abdominal pain [244].

Four RCTs of linaclotide were identified [245–248], one of which had been conducted since the last version of the monograph [245]. In total, these trials recruited 2867 patients. All four trials were at low risk of bias. Summary results favored linaclotide, with a RR of 0.81 (95% CI 0.77 to 0.85), a NNT of 6 (95% CI 5 to 8), and no significant heterogeneity ($I^2=0\%$, $P=0.42$) (Table 1). All four trials also reported on abdominal pain improvement as an endpoint. Again, treatment effects favored linaclotide, with a RR of 0.82 (95% CI 0.75 to 0.89), and a NNT of 8 (95% CI 5 to 14).

Overall adverse events were provided by three trials [245, 247, 248], and were more frequent in the linaclotide arm (RR=1.10; 95% CI 1.01 to 1.19). Individual adverse events were reported by all four trials [245–248]. Diarrhea occurred more frequently in the linaclotide arm (RR=6.81; 95% CI 4.69 to 9.90). The NNH was 7 (95% CI 6 to 11).

Plecanatide

We recommend plecanatide for overall symptom improvement in IBS-C patients. (Recommendation: strong; Quality of evidence: moderate)

Plecanatide is a 16-amino acid peptide similar to uroguanylin, a naturally occurring gut hormone, which also stimulates the enterocyte GC-C receptor but, unlike linaclotide, in a pH-dependent manner. Activation results in electrolyte and fluid transport into the lumen. The drug was initially approved by the Food and Drug Administration (FDA) for the treatment of chronic idiopathic constipation and, more recently, for IBS-C.

There are now published trial data available regarding its effect in patients with IBS-C. Three RCTs were identified, two phase 3 RCTs published in press in a single article [249], and one dose-ranging trial published in abstract form only [250], containing 2612 patients. The two phase 3 RCTs were considered low risk of bias [249]. Pooled data suggests a positive effect of plecanatide on IBS symptoms (RR of remaining symptomatic = 0.88; 95% CI 0.84 to 0.92), with no significant heterogeneity, and a NNT of 10 (95% CI 8 to 14) (Table 1). The quality of evidence was considered moderate due to the modest impact on IBS symptoms.

Total adverse events data were not available for the three studies individually, but were pooled for the two phase 3 trials [249], with 23.8% of patients assigned to 3 mg o.d. of plecanatide reporting any adverse event, 19.8% of those randomized to 6 mg o.d. of plecanatide, and 18.6% of those allocated to placebo [249]. Rates of diarrhea were reported separately for these two RCTs on the company's website [251, 252], and were higher with plecanatide, with a RR of 4.22 (95% CI 1.29 to 13.76). The NNH was 33 (95% CI 20 to 91). Of note, it is difficult to directly compare head-to-head NNH calculations between the two available GC-C agonists, as the definition of 'diarrhea' as an adverse event varies between the clinical trials of linaclotide and plecanatide. Another recent meta-analysis

examining this issue concluded that the numerically lower rates of diarrhea for plecanatide may be related to definitional variations among published trials [253].

Lubiprostone

We recommend lubiprostone for overall symptom improvement in IBS-C patients. (Recommendation: strong; Quality of evidence: moderate)

Lubiprostone is a molecule that activates the intestinal chloride channel type 2 on the apical surface of small intestinal enterocytes. Activation leads to a chloride and water efflux into the luminal cavity, which results in accelerated GI transit.

During this search, no new RCTs of lubiprostone in IBS patients were identified. As such, the assessment of findings and conclusions are unchanged from the previous monograph [4]. Three trials were reported in two papers [254, 255], and all were at low risk of bias. Combined, lubiprostone was superior to placebo with a RR of 0.91 (95% CI 0.87 to 0.95) (Table 1). The NNT was 12.5 (95% CI 8 to 25). The quality of evidence was considered moderate due to the modest impact on IBS symptoms. There was no significant heterogeneity between trial results ($I^2=0\%$, $P=0.92$). Funnel plot asymmetry could not be assessed due to the low number of studies. Adverse events were reported by 66% of patients receiving lubiprostone compared with 58% of patients on placebo (RR = 1.13; 95% CI 0.87 to 1.48). The only symptom occurring more frequently amongst those on active treatment was diarrhea (NNH = 10; 95% CI 5 to 25). Nausea is well-described in patients taking lubiprostone [256], but only one RCT reported these data [255], and there was no significant difference in rates.

Summary. The prosecretory agents linaclotide, plecanatide, and lubiprostone appear to improve symptoms among patients with IBS-C compared with placebo. For all three drugs, the most common side effect was diarrhea.

ELUXADOLINE

We suggest eluxadoline for overall symptom improvement in IBS-D patients. (Recommendation: weak; Quality of evidence: moderate)

Eluxadoline is a μ -opioid and κ -opioid receptor agonist and δ -opioid receptor antagonist in the enteric nervous system, and is FDA-approved for the management of IBS-D.

Three clinical trials, published in two papers [257, 258], and recruiting 3235 IBS-D patients were found. All three studies were low risk of bias. When data were pooled eluxadoline was superior to placebo (RR=0.91; 95% CI 0.85 to 0.97) (Table 1). The NNT was 12.5 (95% CI 8 to 33). However, significant heterogeneity was detected between studies ($I^2=66\%$, $P=0.05$). There was no clear effect on abdominal pain (RR=0.95; 95% CI 0.89 to 1.02) but a statistically significant effect on stool consistency (RR=0.88; 95% CI 0.80 to 0.96), with a NNT of 10 (95% CI 6 to 25). The quality of evidence was considered moderate due to the modest impact on IBS symptoms, and the unexplained heterogeneity between studies.

For the dose of 100 mg twice daily, three trials reported improvement in IBS (RR of symptoms not improving = 0.90; 95% CI 0.86 to 0.95) with a NNT of 13 (95% CI 9 to 24). For the dose of 75 mg twice daily, two trials reported improvement in IBS (RR of symptoms not improving = 0.92; 95% CI 0.87 to 0.97) with a NNT of 15 (95% CI 9 to 40).

Total adverse events from the three trials were reported, but were pooled for the two RCTs reported in a single paper [257]. In the study by Dove et al. [258], overall adverse event rates were comparable in those receiving eluxadoline and placebo (48 v. 49%). However, four cases of pancreatitis were reported with eluxadoline. In the pooled data from the two phase III trials [257], again overall adverse event rates were comparable (59 vs. 56%). Symptoms more common in those receiving eluxadoline included constipation (8 vs. 2.5), nausea (8 vs. 5%), and vomiting (4 vs. 1%). Five cases of pancreatitis were reported with eluxadoline, along with eight cases of sphincter of Oddi spasm.

Summary. Eluxadoline appears to help global symptoms and stool consistency in patients with IBS-D. Because of the risk of pancreatitis, eluxadoline should not be used in patients in whom their gallbladder has been removed or who have a history of sphincter of Oddi problems, pancreatitis, alcohol abuse, alcohol addiction, who drink more than 3 alcoholic drinks a day, or have severe liver problems. Accordingly, the Task Force gave a weak recommendation, despite high quality evidence, due to the fact that the medication may have serious side effects, together with the modest efficacy.

LOPERAMIDE

We suggest against loperamide for overall symptom improvement in IBS patients. (Recommendation: strong; Quality of evidence: very low)

There were no new RCTs of loperamide identified, so we included two trials involving 42 patients [259, 260]. There was no statistically significant effect of loperamide compared with placebo (RR = 0.42; 95% CI 0.14 to 1.42) (Table 1). Both trials stated the type of IBS patients recruited, with 1 study recruiting IBS-M patients [259], and the other IBS-D patients [260].

Both trials provided total numbers of adverse events. There were no adverse events in either arm in one RCT [259] and four adverse events in each arm of the other trial [260].

SEROTONERGIC AGENTS

We suggest alosetron for overall symptom improvement in female IBS-D patients. (Recommendation: weak; Quality of evidence: low)

Serotonin (5-hydroxytryptamine; 5-HT) is implicated in GI secretion, motility, and sensation [261], and a variety of 5-HT receptors have been targets for new drug development in FGIDs [262]. Alosetron, a selective 5-HT₃ antagonist was evaluated in IBS-D and, although it showed efficacy, reports of severe constipation and ischemic colitis led to its withdrawal by the FDA in 2001 [263]. It was re-introduced, via a risk evaluation and mitigation strategy (REMS) for “women suffering with severe IBS-D that is

disabling”. The initial dose of 0.5 mg b.i.d. used via this REMS is lower than that used in the pivotal trials. Other 5-HT₃ antagonists, such as cilansetron and ramosetron, have never been introduced into clinical practice in the US.

Tegaserod is a partial, selective 5-HT₄ agonist, which was granted FDA approval for use in women with IBS-C in 2002. It was withdrawn in 2007, due to possible cardiovascular adverse effects. Tegaserod is the only 5-HT₄ partial agonist that has been evaluated in large, prospective, RCTs in IBS patients. As the drug is no longer available in the US, an updated analysis has not been performed. The interested reader is referred to the previous systematic review [264].

We identified no new studies of alosetron since the previous version of the monograph [4]. There were therefore eight RCTs [265–272], recruiting 4987 patients. Only one trial was at low risk of bias [272], with the remainder unclear. Most trials recruited women only, or predominantly women, with the exception of a US-based trial that recruited only men [271].

Overall, there was a statistically significant effect in favor of alosetron (RR = 0.79; 95% CI 0.69 to 0.90), with a NNT of 7.5 (95% CI 5 to 16), but significant heterogeneity between studies ($I^2 = 85%$, $P < 0.001$) (Table 1). The quality of evidence was rated as low because of concerns around risk of bias and unexplained heterogeneity between studies. There were seven studies evaluating 4607 patients that provided total adverse events data [266–272]. There were significantly more adverse events with alosetron than placebo (RR = 1.19; 95% CI 1.09 to 1.30). The NNH was 10 (95% CI 6 to 20). The main adverse event that was more common with alosetron than with placebo was constipation (NNH = 5; 95% CI 3 to 8).

POLYETHYLENE GLYCOL (PEG)

We suggest against PEG for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: low)

PEG is an osmotic laxative that is not absorbed in the intestinal lumen and is widely available. Its efficacy for constipation has been well established in RCTs [273]. However, its clinical effects in patients with IBS-C are less certain.

Since the previous monograph [4], no new trials were identified, meaning that there were two RCTs assessing PEG in IBS patients. In one RCT at unclear risk of bias [274], containing 42 patients, although bowel movement frequency increased from baseline for both PEG and placebo arms, no statistically significant effect on bowel movements, or pain or discomfort was reported between the active and placebo arms. In the second study [275], which was also at unclear risk of bias and recruited 139 patients with IBS-C, there was an increase in spontaneous bowel movements compared with placebo at 4 weeks. Although pain scores decreased from baseline, no significant effect on abdominal pain or discomfort was seen with PEG compared with placebo. There was also a trend toward greater improvement in bloating in the PEG arm ($P = 0.06$). Adverse event rates were slightly higher in patients receiving PEG compared with placebo in one RCT (38.8 vs. 32.9%; 16.4 vs. 8.6% of which were possibly/probably treatment-related) [275]. The most common treatment-related symptoms were abdominal pain (6 vs. 0%), and diarrhea (4.5 vs. 4.3%).

Summary. PEG improved frequency of bowel movements in IBS-C, but not pain or other IBS-related symptoms.

5-AMINOSALICYLATES IN IBS

We suggest against 5-aminosalicylates (5-ASAs) for overall symptom improvement in IBS patients. (Recommendation: weak; Quality of evidence: low)

Based on studies in post-infectious IBS [276], as well as IBS in general [277, 278], that a state of low grade-inflammation or immune activation is present in some subjects, the hypothesis that anti-inflammatory compounds, such as those used widely in inflammatory bowel disease [279, 280], might be effective in IBS has been explored.

We identified three RCTs of 5-ASAs in IBS [281–283], all of which used mesalamine, and contained 464 patients. Two RCTs were at low risk of bias [281, 282]. One trial used a dose of either 750 mg or 1.5 g mesalamine o.d. [283], one trial used a dose of 2 g b.i.d. [282], and the third used 800 mg t.i.d. [281]. All individual studies were negative, according to their primary end-points, evaluating all doses of 5-ASA. When all data were pooled according to predefined criteria for this monograph there was a significant effect of mesalamine in reducing symptoms in IBS compared with placebo (RR of IBS symptoms not improving = 0.85; 95% CI 0.75 to 0.97), and no significant heterogeneity between individual trial results ($I^2 = 0\%$, $P = 0.45$) (Table 1). The NNT with mesalamine was 9 (95% CI 5 to 50). However, this result was not robust and, if author-defined primary end-points were used, the results were not statistically significant (RR = 0.90; 95% CI = 0.77 to 1.06). Data on overall adverse events were not reported in any of the three trials. Individual adverse events were reported in two trials [281, 282], but were rare, and none were more frequent with mesalamine.

Summary. Although our systematic review did suggest a benefit of 5-ASAs in relieving IBS symptoms, this result depended on the end-point used, and the Task Force felt that the data were too fragile to recommend this intervention in IBS. These data, however, suggest that 5-ASAs should be further studied in adequately powered RCTs in IBS, as there is a possibility that these drugs may be modestly efficacious in improving symptoms.

ACKNOWLEDGEMENTS

We are grateful to Cathy Yuan for conducting the search strategy for the antimicrobial and food sections of the monograph, as well as assessing eligibility and extracting the data with Paul Moayyedi for these sections. PM is supported by a Canadian Institute for Health Research grant as Principal Investigator for the Inflammation, microbiome, and alimentation: gastro-intestinal and neuropsychiatric effects (IMAGINE)-a Strategy for Patient Oriented Research (SPOR) chronic disease network that evaluates the role of the microbiome and diet in IBS.

CONFLICT OF INTERESTS

Guarantor of the article: Eamonn M.M. Quigley

Specific author contributions: AF and PM performed the meta-analyses, provided first drafts of systematic reviews on each section,

and wrote the sections on methodology. Individual therapeutics sections were then completed by WDC, LAH, BEL, YAS, and EMMQ. All authors participated in the consensus meeting. Following consensus, EMMQ collated these sections and provided a completed draft which was then reviewed and ultimately approved by all authors.

Financial support: An unrestricted educational grant has been provided to the ACG Institute for Clinical Research and Education from Allergan and Ironwood Pharmaceuticals. The ACG Institute for Clinical Research and Education would also like to acknowledge sponsorship of the monograph from IM HealthScience. The analysis that supports this monograph and its writing was conducted on behalf of the American College of Gastroenterology's ACG Institute for Clinical Research and Education by the ACG's Task Force on Management of Irritable Bowel Syndrome, which had complete scientific and editorial control of its content and whose work was supported exclusively by the ACG Institute. Readers should note that the work of the systematic review was conducted before funding was obtained.

Potential competing interests: EMMQ has served as a consultant and/or on the advisory board for Alimentary Health, Allergan, Biocodex, Commonwealth Laboratories, 4D Pharma, Menarini, Rhythm, Salix, Shire, Synergy, and Vibrant, has served as a speaker for Allergan, Biocodex, Pharmasierra, and Sanofi, has received research support from 4D, Allergan, Rhythm, Theravance, and Vibrant, and has been a non-executive director, shareholder, and patent holder for Alimentary Health. ACF has served as a consultant and/or on the advisory board for Ipsen Pharma SPA, and has served as a speaker for Norgine. PM has served as consultant and/or on the advisory board for Allergan, Lupin, Shire, and Takeda, has served as a speaker for Allergan, and has received research support from Allergan and Takeda. WDC has served as a consultant and/or on the advisory board for Allergan, Biomerica, IM Health, Ironwood, Nestle, Outpost, Prometheus, Ritter, Salix, QoL, and Valeant, has received research support from Ironwood and Nestle, and has been a non-executive director, shareholder, and patent holder for My Total Health. LAH has served as a consultant and/or on the advisory board for Allergan, IM Health Science, Ironwood, Napo Pharmaceuticals, Salix, Shire, and Synergy, and has served as a speaker for Allergan and Ironwood. BEL has served as a consultant and/or on the advisory board for Allergan, Ironwood, and Salix, has served as a speaker for Lupine, has received research support from Covidien. YAS has served as a consultant and/or on the advisory board for Ironwood, Synergy, Outpost Medicine, and Monash University, and has received research support from Salix.

CONTINUING MEDICAL EDUCATION

To receive CME/MOC credit for this monograph, please go to: <http://acgjournalcme.gi.org>.

REFERENCES

1. Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. *Aliment Pharmacol Ther.* 2005;21:1365–75.
2. Lovell RM, Ford AC. Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis. *Clin Gastroenterol Hepatol.* 2012; 10:712–21.

3. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. *Am J Gastroenterol.* 2012;107:991–1000.
4. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. *Am J Gastroenterol.* 2014;109:S2–26.
5. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. *Gastroenterology.* 2016;150:1393–407.
6. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. *N Engl J Med.* 2017;376:2566–78.
7. Cash B, Sullivan S, Barghout V. Total costs of IBS: employer and managed care perspective. *Am J Manag Care.* 2005;11:S7–16.
8. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. *Am J Gastroenterol.* 2003;98:600–7.
9. Ladabaum U, Boyd E, Zhao WK, et al. Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. *Clin Gastroenterol Hepatol.* 2012;10:37–45.
10. Lacy BE, Patel H, Guerin A, et al. Variation in care for patients with irritable bowel syndrome in the United States. *PLoS One.* 2016;11:e0154258.
11. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. *Am J Manag Care.* 2005;11:S17–26.
12. Creed F, Ratcliffe J, Fernandez L, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. *Ann Intern Med.* 2001;134:860–8.
13. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: A meta-analysis. *Am J Med.* 2000;108:65–72.
14. Jaliwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. *Ann Intern Med.* 2000;133:136–47.
15. Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther.* 2004;20:1253–69.
16. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and meta-analysis. *Am J Gastroenterol.* 1998;93:1131–5.
17. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther.* 2001;15:355–61.
18. Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. *Cochrane Database Syst Rev.* 2005;18:CD003460.
19. Tack J, Fried M, Houghton LA, et al. Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. *Aliment Pharmacol Ther.* 2006;24:183–205.
20. Evans BW, Clark WK, Moore DJ, et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. *Cochrane Database Syst Rev.* 2007;(4):CD003960.
21. Jones BW, Moore DJ, Robinson SM, et al. A systematic review of tegaserod for the treatment of irritable bowel syndrome. *J Clin Pharmacol.* 2002;27:343–52.
22. Anonymous. Systematic review on the management of irritable bowel syndrome in the European Union. *Eur J Gastroenterol Hepatol.* 2007;19:S11–S37.
23. Ford AC, Guyatt GH, Talley NJ, et al. Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. *Am J Gastroenterol.* 2010;105:280–8.
24. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. *Am J Gastroenterol.* 2014;109:1547–61.
25. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. *Am J Gastroenterol.* 2014;109:1350–65.
26. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. *Am J Gastroenterol.* 2014;109:1367–74.
27. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of dietary intervention on irritable bowel syndrome: a systematic review. *Clin Transl Gastroenterol.* 2015;6:e107.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* 1986;7:177–88.
29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002;21:1539–58.
30. Egger M, Davey-Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ.* 1997;315:629–34.
31. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ.* 2011;343:d4002.
32. Harnett T. Consensus-Oriented Decision-Making: the CODM Model for Facilitating Groups to Widespread Agreement. New Society Publishers. 2011.
33. Lee PG, Jackson EA, Richardson CR. Exercise prescriptions in older adults. *Am Fam Physician.* 2017;95:425–32.
34. Herring MP, Puetz TW, O'Connor PJ, et al. Effect of exercise training on depressive symptoms among patients with a chronic illness: A systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med.* 2012;172:101–11.
35. Ohlsson B, Manjer J. Physical inactivity during leisure time and irregular meals are associated with functional gastrointestinal complaints in middle-aged and elder subjects. *Scand J Gastroenterol.* 2016;51:1299–307.
36. Villoria A, Serra J, Azpiroz F, et al. Physical activity and intestinal gas clearance in patients with bloating. *Am J Gastroenterol.* 2006;101:2552–7.
37. Song BK, Cho KO, Jo Y, et al. Colon transit time according to physical activity level in adults. *J Neurogastroenterol Motil.* 2012;18:64–9.
38. Daley AJ, Grimmett C, Roberts L, et al. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. *Int J Sports Med.* 2008;29:778–82.
39. Johannesson E, Simren M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. *Am J Gastroenterol.* 2011;106:915–22.
40. Johannesson E, Ringstrom G, Abrahamsson H, et al. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. *World J Gastroenterol.* 2015;21:600–8.
41. Hayes PA, Fraher MH, Quigley EM. Irritable bowel syndrome: the role of food in pathogenesis and management. *Gastroenterol Hepatol (N Y).* 2014;10:164–74.
42. McKenzie YA, Bowyer RK, Leach H, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). *J Hum Nutr Diet.* 2016;29:549–75.
43. Eswaran SL, Chey WD, Han-Markey T, et al. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. *Am J Gastroenterol.* 2016;111:1824–32.
44. Bohn L, Storsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. *Gastroenterology.* 2015;149:1399–e2.
45. McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. *Gut.* 2017;66:1241–51.
46. Staudacher HM, Lomer MC, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. *J Nutr.* 2012;142:1510–8.
47. Staudacher HM, Lomer MCE, Farquharson FM, et al. Diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and probiotic restores Bifidobacterium species: A randomized controlled trial. *Gastroenterology.* 2017;153:936–47.
48. Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology.* 2014;146:67–75.
49. Hustoft TN, Hausken T, Ystad SO et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. *Neurogastroenterol Motil.* 2017;29:<https://doi.org/10.1111/nmo>.
50. Krogsgaard LR, Lyngesen M, Bytzer P. Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome. *Aliment Pharmacol Ther.* 2017;45:1506–13.
51. Chumpitazi BP, Cope JL, Hollister EB, et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. *Aliment Pharmacol Ther.* 2015;42:418–27.
52. Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. *Gut.* 2015;64:93–100.

53. Bennet SMP, Bohn L, Storsrud S, et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. *Gut*. 2017; <https://doi.org/10.1136/gutjnl-2016-313128>.
54. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. *Am J Gastroenterol*. 2011;106:508–14.
55. Shahbazkhani B, Sadeghi A, Malekzadeh R, et al. Non-celiac gluten sensitivity has narrowed the spectrum of irritable bowel syndrome: a double-blind randomized placebo-controlled trial. *Nutrients*. 2015;7:4542–54.
56. Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. *Gut*. 2004;53:1459–64.
57. Ali A, Weiss TR, McKee D, et al. Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial. *BMJ Open Gastroenterol*. 2017;4:e000164.
58. Soltoft J, Krag B, Gudmand-Hoyer E, et al. A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. *Lancet*. 1976;307:270–2.
59. Manning AP, Heaton KW, Harvey RF, et al. Wheat fibre and irritable bowel syndrome: a controlled trial. *Lancet*. 1977;310:417–8.
60. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. *BMJ*. 1979;278:376–8.
61. Longstreth GF, Fox DD, Youkeles L, et al. Psyllium therapy in the irritable bowel syndrome: a double-blind trial. *Ann Intern Med*. 1981;95:53–56.
62. Arthurs Y, Fielding JF. Double blind trial of ispaghula/poloxamer in the irritable bowel syndrome. *Ir Med J*. 1983;76:253.
63. Nigam P, Kapoor KK, Rastog CK, et al. Different therapeutic regimens in irritable bowel syndrome. *J Assoc Physicians India*. 1984;32:1041–4.
64. Kruis W, Weinzierl M, Schussler P, et al. Comparison of the therapeutic effects of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. *Digestion*. 1986;34:196–201.
65. Lucey MR, Clark ML, Lowndes JO, et al. Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. *Gut*. 1987;28:221–5.
66. Prior A, Whorwell P. Double blind study of ispaghula in irritable bowel syndrome. *Gut*. 1987;28:1510–3.
67. Jaliha A, Kurian G. Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction. *J Gastroenterol Hepatol*. 1990;5:507–13.
68. Fowlie S, Eastwood MA, Prescott R. Irritable bowel syndrome: assessment of psychological disturbance and its influence on the response to fibre supplementation. *J Psychosom Res*. 1992;36:175–80.
69. Rees G, Davies J, Thompson R, et al. Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome. *J R Soc Health*. 2005;125:30–34.
70. Bijkerk CJ, de Wit NJ, Muris JW, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. *BMJ*. 2009;339:b3154.
71. Cockerell KM, Watkins AS, Reeves LB, et al. Effects of linseeds on the symptoms of irritable bowel syndrome: a pilot randomised controlled trial. *J Hum Nutr Diet*. 2012;25:435–43.
72. Kamiya T, Shikano M, Tanaka M, et al. Therapeutic effects of biobran, modified arabinoxylan rice bran, in improving symptoms of diarrhea predominant or mixed type irritable bowel syndrome: a pilot, randomized controlled study. *Evid Based Complement Altern Med*. 2014;2014:828137.
73. Thabane M, Kottachchi D, Marshall JK. Systematic review and meta-analysis: incidence and prognosis of post-infectious irritable bowel syndrome. *Aliment Pharmacol Ther*. 2007;26:535–44.
74. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. *Am J Gastroenterol*. 2000;95:3503–6.
75. Jalanka-Tuovinen J, Salojärvi J, Salonen A, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. *Gut*. 2014;63:1737–45.
76. Codling C, O'Mahony L, Shanahan F, et al. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. *Dig Dis Sci*. 2010;55:392–7.
77. Jeffery IB, O'Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. *Gut*. 2012;61:997–1006.
78. Tap J, Derrien M, Tornblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. *Gastroenterology*. 2017;152:111–e8.
79. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*. 2014;11:506–14.
80. Alexea O, Bacarea V, Pique N. The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial. *United European Gastroenterol J*. 2016;4:455–65.
81. Tsuchiya J, Barreto R, Okura R, et al. Single-blind follow up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. *Chin J Dig Dis*. 2004;5:169–74.
82. Min YW, Park SU, Jang YS, et al. Effect of composite yogurt enriched with acacia fiber and *Bifidobacterium lactis*. *World J Gastroenterol*. 2012;18:4563–9.
83. Kabir MA, Ishaque SM, Ali MS, et al. Role of *Saccharomyces boulardii* in diarrhea predominant irritable bowel syndrome. *Mymensingh Med J*. 2011;20:397–401.
84. Ko SJ, Han G, Kim SK, et al. Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. *Evid Based Complement Altern Med*. 2013;2013:824605.
85. Stevenson C, Blaauw R, Fredericks E, et al. Randomized clinical trial: effect of *Lactobacillus plantarum* 299 v on symptoms of irritable bowel syndrome. *Nutrition*. 2014;30:1151–7.
86. Sisson G, Ayis S, Sherwood RA, et al. Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome—a 12 week double-blind study. *Aliment Pharmacol Ther*. 2014;40:51–62.
87. Jafari E, Vahedi H, Merat S, et al. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. *Arch Iran Med*. 2014;17:466–70.
88. Ludidi S, Jonkers DM, Koning CJ, et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. *Neurogastroenterol Motil*. 2014;26:705–14.
89. Yoon JS, Sohn W, Lee OY, et al. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. *J Gastroenterol Hepatol*. 2014;29:52–9.
90. Abbas Z, Yakoub J, Jafri W, et al. Cytokine and clinical response to *Saccharomyces boulardii* therapy in diarrhea-dominant irritable bowel syndrome: A randomized trial. *Eur J Gastroenterol Hepatol*. 2014;26:630–9.
91. Lorenzo-Zuniga V, Llop E, Suarez C, et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. *World J Gastroenterol*. 2014;20:8709–16.
92. Pineton de Chambrun G, Neut C, Chau A, et al. A randomized clinical trial of *Saccharomyces cerevisiae* versus placebo in the irritable bowel syndrome. *Dig Liver Dis*. 2015;47:119–24.
93. Wong RK, Yang C, Song GH, et al. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: A randomized double-blinded placebo study. *Dig Dis Sci*. 2015;60:186–94.
94. Yoon H, Park YS, Lee DH, et al. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *J Clin Biochem Nutr*. 2015;57:129–34.
95. Thijssen AY, Clemens CH, Vankerckhoven V, et al. Efficacy of *Lactobacillus casei* Shirota for patients with irritable bowel syndrome. *Eur J Gastroenterol Hepatol*. 2016;28:8–14.
96. Spiller R, Pelerin F, Cayzele Decherf A, et al. Randomized double blind placebo-controlled trial of *Saccharomyces cerevisiae* CNCM I-3856 in irritable bowel syndrome: Improvement in abdominal pain and bloating in those with predominant constipation. *U Eur Gastroenterol J*. 2016;4:353–62.
97. Hod K, Sperber AD, Ron Y et al. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. *Neurogastroenterol Motil*. 2017;29: <https://doi.org/10.1111/nmo>.
98. Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Probiotic *Bifidobacterium longum* NCC3001 reduces depression scores and alters brain activity: A pilot study in patients with irritable bowel syndrome. *Gastroenterology*. 2017;153:448–59.

99. Lyra A, Hillila M, Huttunen T, et al. Irritable bowel syndrome severity improves equally with probiotic and placebo. *World J Gastroenterol.* 2016;22:10631–42.
100. Gade J, Thorn P. Paraguhurt for patients with irritable bowel syndrome. *Scand J Prim Health Care.* 1989;7:23–26.
101. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. *Am J Gastroenterol.* 2000;95:1231–8.
102. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double blind, randomized study on the efficacy of *Lactobacillus plantarum* 299V in patients with irritable bowel syndrome. *Eur J Gastroenterol Hepatol.* 2001;13:1143.
103. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther.* 2003;17:895–904.
104. Kajander K, Hatakka K, Poussa T, et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. *Aliment Pharmacol Ther.* 2005;22:387–94.
105. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. *Neurogastroenterol Motil.* 2005;17:687–96.
106. Niv E, Naftali T, Hallak R, et al. The efficacy of *Lactobacillus reuteri* ATCC 55730 in the treatment of patients with irritable bowel syndrome - A double blind, placebo-controlled, randomized study. *Clin Nutr.* 2005;24:925–31.
107. O'Mahony L, McCarthy J, Kelly P, et al. *Lactobacillus* and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterology.* 2005;128:541–51.
108. Kim YG, Moon JT, Lee KM, et al. The effects of probiotics on symptoms of irritable bowel syndrome. *Korean J Gastroenterol.* 2006;47:413–9.
109. Simren M, Syrous A, Lindh A, et al. Effects of *Lactobacillus Plantarum* 299V on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS) - A randomized double blind controlled trial. *Gastroenterology.* 2006;130:A600.
110. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic *Bifidobacterium infantis* 35624 in women with irritable bowel syndrome. *Am J Gastroenterol.* 2006;101:1581–90.
111. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing *Bifidobacterium animalis* DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double blind, controlled trial. *Aliment Pharmacol Ther.* 2007;26:475–86.
112. Drouault-Holowacz S, Bieuevet S, Burckel A, et al. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. *Gastroenterol Clin Biol.* 2008;32:147–52.
113. Enck P, Zimmerman K, Menke G, et al. A mixture of *Escherichia coli* (DSM 17252) and *Enterococcus faecalis* (DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians. *Neurogastroenterol Motil.* 2008;20:1103–9.
114. Kajander K, Myllyluoma E, Rajilik-Stojanovic M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. *Aliment Pharmacol Ther.* 2008;27:48–57.
115. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of *Lactobacillus acidophilus* -SDC 2012, 2013 in patients with irritable bowel syndrome. *Dig Dis Sci.* 2008;53:2714–8.
116. Zeng J, Li YQ, Zuo XL, et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther.* 2008;28:994–1002.
117. Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing *Bifidobacterium lactis* DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. *Aliment Pharmacol Ther.* 2009;29:104–14.
118. Enck P, Zimmerman K, Menke G, et al. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic *E.-coli* preparation (DSM17252) compared to placebo. *Z Gastroenterol.* 2009;47:209–14.
119. Hong KS, Kang HW, Im JP, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. *Gut Liver.* 2009;3:101–7.
120. Williams EA, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. *Aliment Pharmacol Ther.* 2009;29:97–103.
121. Simren M, Ohman L, Olsson J, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - A randomized, double-blind, controlled study. *Aliment Pharmacol Ther.* 2010;31:218–27.
122. Choi CH, Jo SY, Park HJ, et al. A randomized, double-blind, placebo-controlled multicenter trial of *Saccharomyces boulardii* in irritable bowel syndrome: Effect on quality of life. *J Clin Gastroenterol.* 2011;45:679–83.
123. Guglielmetti S, Mora D, Gschwender M, et al. Randomised clinical trial: *Bifidobacterium bifidum* MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - A double-blind, placebo-controlled study. *Aliment Pharmacol Ther.* 2011;33:1123–32.
124. Michail S, Kenche H. Gut microbiota is not modified by randomized, double-blind, placebo-controlled trial of VSL#3 in diarrhea-predominant irritable bowel syndrome. *Probiotics Antimicrob Proteins.* 2011;3:1–7.
125. Ringel-Kulka T, Palsson OS, Maier D, et al. Probiotic bacteria *Lactobacillus acidophilus* NCFM and *Bifidobacterium lactis* Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. *J Clin Gastroenterol.* 2011;45:518–25.
126. Sondergaard B, Olsson J, Ohlson K, et al. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. *Scand J Gastroenterol.* 2011;46:663–72.
127. Cha BK, Jung SM, Choi CH, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *J Clin Gastroenterol.* 2012;46:220–7.
128. Cui S, Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. *Int J Clin Exp Med.* 2012;5:238–44.
129. Dapoigny M, Piche T, Ducrotte P, et al. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. *World J Gastroenterol.* 2012;18:2067–75.
130. Ducrotte P, Sawant P, Jayanthi V. Clinical trial: *Lactobacillus plantarum* 299v (DSM 9843) improves symptoms of irritable bowel syndrome. *World J Gastroenterol.* 2012;18:4012–8.
131. Farup PG, Jacobsen M, Ligaarden SC, et al. Probiotics, symptoms, and gut microbiota: What are the relations? A randomized controlled trial in subjects with irritable bowel syndrome. *Gastroenterol Res Pract.* 2012;2012:214102.
132. Kruijs W, Chrubasik S, Boehm S, et al. A double-blind placebo-controlled trial to study therapeutic effects of probiotic *Escherichia coli* Nissle 1917 in subgroups of patients with irritable bowel syndrome. *Int J Colorectal Dis.* 2012;27:467–74.
133. Begtrup LM, de Muckadell OB, Kjeldsen J, et al. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome - a randomised, double-blind, placebo controlled trial. *Scand J Gastroenterol.* 2013;48:1127–35.
134. Roberts LM, McCahon D, Holder R, et al. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. *BMC Gastroenterol.* 2013;13:45.
135. Ghoshal UC, Srivastava D, Misra A, et al. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. *Eur J Gastroenterol Hepatol.* 2016;28:281–9.
136. Lombardo L, Schembri M. A reason why lactose-free diet can be clinically ineffective in lactose intolerance patients. *U Eur Gastroenterol J.* 2015;3:A54.
137. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. *Gastroenterology.* 2016;151:1113–21.
138. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. *Am J Gastroenterol.* 2003;98:412–9.
139. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. *Am J Gastroenterol.* 2006;101:326–33.
140. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. *Ann Intern Med.* 2006;145:557–63.
141. Lembo A, Zakko SF, Ferreira NL, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: Short term treatment leading to long term sustained response. *Gastroenterology.* 2008;134:A545.

142. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. *N Engl J Med*. 2011;364:22–32.
143. Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. *Aliment Pharmacol Ther*. 2014;39:1161–8.
144. Acosta A, Camilleri M, Shin A, et al. Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. *Clin Transl Gastroenterol*. 2016;7:e173.
145. Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. *Clin Exp Gastroenterol*. 2015;8:309–25.
146. Kim MS, Morales W, Hani AA, et al. The effect of rifaximin on gut flora and *Staphylococcus* resistance. *Dig Dis Sci*. 2013;58:1676–82.
147. Zeber-Lubecka N, Kulecka M, Ambrozkiwicz F, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. *Gut Microbes*. 2016;7:397–413.
148. www.accessdata.fda.gov/drugsatfda_docs/label/2015/021361s0121b1ed.pdf. 2015.
149. Rai RR, Dwivedi M, Kumar N. Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: a randomized double-blind placebo-controlled study. *Saudi J Gastroenterol*. 2014;20:378–82.
150. Zheng L, Lai Y, Lu W, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multi-center, randomized controlled trial. *Clin Gastroenterol Hepatol*. 2015;13:1285–92.
151. Misra SC, Pandey RM. Efficacy of drotaverine in irritable bowel syndrome: a double blind, randomized, placebo-controlled clinical trial. *Am J Gastroenterol*. 2000;95:2544.
152. Schafer VE, Ewe K. The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon. *Fortschr Med*. 1990;108:488–92.
153. Centonze V, Imbibo BP, Campanozzi F, et al. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. *Am J Gastroenterol*. 1988;83:1262–6.
154. Dobrilla G, Imbibo BP, Piazzi L, et al. Long term treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. *Gut*. 1990;31:355–8.
155. Passaretti S, Guslandi M, Imbibo BP, et al. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. *Aliment Pharmacol Ther*. 1989;3:276.
156. Delmont J. Interet de l'adjonction d'un antispasmodique musculotrope au traitement des constipations douloureuses des colopathies fonctionnelles par le son. *Med Chir Dig*. 1981;10:365–70.
157. Levy C, Charbonnier A, Cachin M. Pinaverium bromide and functional colonic disease (double-blind study). *Sem Hop Ther*. 1977;53:372–4.
158. Virat J, Hueber D. Colopathy pain and dicetel. *Prat Med*. 1987;43:32–34.
159. Fielding JF. Double blind trial of trimebutine in the irritable bowel syndrome. *Ir Med J*. 1980;73:377–9.
160. Ghidini O, Saponati G, Intrieri L. Single drug treatment for irritable colon: Rociverine versus trimebutine maleate. *Curr Ther Res Clin Exp*. 1986;39:541–8.
161. Moshal MG, Herron M. A clinical trial of trimebutine (Mebutin) in spastic colon. *J Int Med Res*. 1979;7:231–4.
162. D'Arienzo A, D'Agostino L. Lottilonio bromuro nel trattamento della sindrome del colon irritabile. *Rass Int Clin Ter*. 1980;60:649–56.
163. Glende M, Morselli-Labate AM, Battaglia G, et al. Extended analysis of a double blind, placebo-controlled, 15-week study with otilinum bromide in irritable bowel syndrome. *Eur J Gastroenterol Hepatol*. 2002;14:1331–8.
164. Gilvarry J, Kenny A, Fielding JF. The non-effect of pirenzepine in dietary resistant irritable bowel syndrome. *Ir J Med Sci*. 1989;158:262.
165. Mitchell SA, Mee AS, Smith GD, et al. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: Results of a double-blind, randomized, placebo-controlled trial. *Aliment Pharmacol Ther*. 2002;16:1187–95.
166. Piai G, Mazzacca G. Prifinium bromide in the treatment of the irritable colon syndrome. *Gastroenterology*. 1979;77:500–2.
167. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Betyl (dicyclomine hydrochloride). *J Clin Gastroenterol*. 1981;3:153–6.
168. Baldi F, Corinaldesi R, Ferrarini F, et al. Clinical and functional evaluation of otilonium bromide in the treatment of irritable bowel syndrome: a double-blind controlled trial. *Clin Trials J*. 1983;20:77–88.
169. Castiglione F, Daniele B, Mazzacca G. Therapeutic strategy for the irritable bowel syndrome. *Ital J Gastroenterol*. 1991;23:53–55.
170. Pulpeiro A, Marti ML, De Los Santos AR, et al. Propinox en síndrome de intestino irritable. *Prensa Med Argent*. 2000;87:299–307.
171. Clave P, Acalovschi M, Triantafyllidis JK, et al. Randomised clinical trial: Otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. *Aliment Pharmacol Ther*. 2011;34:432–42.
172. Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. *Dig Dis Sci*. 2016;61:560–71.
173. Mosaffa-Jahromi M, Lankarani KB, Pasalar M, et al. Efficacy and safety of enteric coated capsules of anise oil to treat irritable bowel syndrome. *J Ethnopharmacol*. 2016;194:937–46.
174. Lech Y, Olesen KM, Hey H, et al. Treatment of irritable bowel syndrome with peppermint oil. A double-blind investigation with a placebo. *Ugeskr Laege*. 1988;150:2388–9.
175. Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. *J Gastroenterol*. 1997;32:765–8.
176. Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. *Dig Liver Dis*. 2007;39:530–6.
177. Capanni M, Surrenti E, Biagini M, et al. Efficacy of peppermint oil in the treatment of irritable bowel syndrome: a randomized, controlled trial. *Gazz Med Ital*. 2005;164:119–26.
178. Merat S, Khalili S, Mostajabi P, et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. *Dig Dis Sci*. 2010;55:1385–90.
179. McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: Is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. *Dig Dis Sci*. 1993;38:1761–2.
180. Irvine EJ, Tack J, Crowell MD, et al. Design of treatment trials for functional gastrointestinal disorders. *Gastroenterology*. 2016;150:1469–e1.
181. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. *J Clin Gastroenterol*. 2014;48:505–12.
182. Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. *Am J Gastroenterol*. 2012;107:1793–801.
183. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. *Annu Rev Med*. 2011;62:381–96.
184. Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. *Eur Arch Psychiatry Clin Neurosci*. 2014;264:651–60.
185. Patel P, Bercik P, Morgan DG, et al. Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. *Aliment Pharmacol Ther*. 2015;14:13074.
186. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut oro-caecal transit times in health and irritable bowel syndrome. *Aliment Pharmacol Ther*. 1994;8:159–66.
187. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. *Dig Dis Sci*. 1995;40:86–95.
188. Agger JL, Schroder A, Gormsen LK, et al. Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): A double-blind, randomised study. *Lancet Psychiatry*. 2017;4:378–88.
189. Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. *Psychosomatics*. 1978;19:540–7.
190. Myren J, Groth H, Larssen SE, et al. The effect of trimipramine in patients with the irritable bowel syndrome: a double-blind study. *Scand J Gastroenterol*. 1982;17:871–5.
191. Boerner D, Eberhardt R, Metz K, et al. Wirksamkeit und verträglichkeit eines antidepressivums beim colon irritabile. *Therapiewoche*. 1988;38:201–8.
192. Bergmann M, Heddergott A, Schlosser T. [Die therapie des colon irritabile mit trimipramin (Herphonal) - Eine kontrollierte studie]. *Z Klin Med*. 1991;46:1621–8.
193. Vij JC, Jiloha RC, Kumar N, et al. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. *Indian J Psychiatry*. 1991;33:243–6.
194. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. *Gastroenterology*. 2003;125:19–31.

195. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. *Clin Gastroenterol Hepatol.* 2003;1:219–28.
196. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high fiber diet: a double-blind placebo-controlled trial. *Am J Gastroenterol.* 2004;99:914–20.
197. Vahedi H, Merat S, Momtahan S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther.* 2008;27:678–84.
198. Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. *Aliment Pharmacol Ther.* 2005;22:381–5.
199. Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. *Gut.* 2006;55:1095–103.
200. Talley NJ, Kellow JE, Boyce P, et al. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. *Dig Dis Sci.* 2008;53:108–15.
201. Abdul-Baki H, El Hajj II, ElZahabi L, et al. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. *World J Gastroenterol.* 2009;15:3636–42.
202. Masand PS, Pae CU, Krulwicz S, et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. *Psychosomatics.* 2009;50:78–86.
203. Ladabaum U, Sharabidze A, Levin TR, et al. Citalopram is not effective therapy for nondepressed patients with irritable bowel syndrome. *Clin Gastroenterol Hepatol.* 2010;8:42–48.
204. Ghadir MR, Habibinejad H, Heidari A, et al. Doxepin is more effective than nortriptyline and placebo for the treatment of diarrhea-predominant irritable bowel syndrome: a randomized triple-blind placebo-controlled trial. *Tehran Univ Med J.* 2011;69:352–8.
205. Cording M, Derry S, Phillips T, et al. Milnacipran for pain in fibromyalgia in adults. *Cochrane Database Syst Rev.* 2015;(10):CD008244.
206. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. *Cochrane Database Syst Rev.* 2014;(1):CD007115.
207. Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. *Eur J Neurol.* 2009;16:1041–8.
208. Skljarevski V, Zhang S, Desai D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. *J Pain.* 2010;11:1282–90.
209. Konno S, Oda N, Ochiai T, et al. Randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in Japanese patients With chronic low back pain. *Spine.* 2016;41:1709–17.
210. Kaplan A, Franzen MD, Nickell PV, et al. An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. *Int J Psychiatry Clin Pract.* 2014;18:11–5.
211. Greene B, Blanchard EB. Cognitive therapy for irritable bowel syndrome. *J Consult Clin Psychol.* 1994;62:576–82.
212. Kennedy T, Jones R, Darnley S, et al. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. *BMJ.* 2005;331:435–7.
213. Payne A, Blanchard EB. A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. *J Consult Clin Psychol.* 1995;63:779–86.
214. Tkachuk GA, Graff LA, Martin GL, et al. Randomized controlled trial of cognitive-behavioral group therapy for irritable bowel syndrome in a medical setting. *J Clin Psychol Med Settings.* 2003;10:57–69.
215. Vollmer A, Blanchard EB. Controlled comparison of individual versus group cognitive therapy for irritable bowel syndrome. *Behav Ther.* 1998;29:19–33.
216. Blanchard EB, Greene B, Scharff L, et al. Relaxation training as a treatment for irritable bowel syndrome. *Biofeedback Self Regul.* 1993;18:125–31.
217. Keefer L, Blanchard EB. The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study. *Behav Res Ther.* 2001;39:801–11.
218. Lynch PM, Zamble E. A controlled behavioral treatment study of irritable bowel syndrome. *Behav Ther.* 1989;20:509–23.
219. van der Veek PPJ, van Rood YR, Masclee AAM. Clinical trial: short- and long-term benefit of relaxation training for irritable bowel syndrome. *Aliment Pharmacol Ther.* 2007;26:943–52.
220. Shinozaki M, Kanazawa M, Kano M, et al. Effect of autogenic training on general improvement in patients with irritable bowel syndrome: a randomized controlled trial. *Appl Psychophysiol Biofeedback.* 2010;35:189–98.
221. Moser G, Tragner S, Elwira Gajowniczek E, et al. Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. *Am J Gastroenterol.* 2013;108:602–9.
222. Galovski TE, Blanchard EB. The treatment of irritable bowel syndrome with hypnotherapy. *Appl Psychophysiol Biofeedback.* 1998;23:219–32.
223. Simren M, Ringstrom G, Bjorsson ES, et al. Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. *Psychosom Med.* 2004;66:233–8.
224. Lindfors P, Unge P, Arvidsson P, et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings - Results from two randomized, controlled trials. *Am J Gastroenterol.* 2012;107:276–85.
225. Neff DF, Blanchard EB. A multi-component treatment for irritable bowel syndrome. *Behav Ther.* 1987;18:70–83.
226. Heitkemper M, Jarrett ME, Levy RL, et al. Self-management for women with irritable bowel syndrome. *Clin Gastroenterol Hepatol.* 2004;2:585–96.
227. Blanchard EB, Schwarz SP, Suls JM, et al. Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome. *Behav Res Ther.* 1992;30:175–89.
228. Sanders KA, Blanchard EB, Sykes MA. Preliminary study of a self-administered treatment for irritable bowel syndrome: Comparison to a wait list control group. *Appl Psychophysiol Biofeedback.* 2007;32:111–9.
229. Moss-Morris R, McAlpine L, Didsbury LP, et al. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. *Psychol Med.* 2010;40:85–94.
230. Hunt MG, Moshier S, Milonova M. Brief cognitive-behavioral internet therapy for irritable bowel syndrome. *Behav Res Ther.* 2009;47:797–802.
231. Ljotsson B, Falk L, Wibron Vesterlund A, et al. Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome - A randomized controlled trial. *Behav Res Ther.* 2010;48:531–9.
232. Guthrie E, Creed F, Dawson D, et al. A controlled trial of psychological treatment for the irritable bowel syndrome. *Gastroenterology.* 1991;100:450–7.
233. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. *Gastroenterology.* 2003;124:303–17.
234. Zernicke KA, Campbell TS, Blustein PK, et al. Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: A randomized wait-list controlled trial. *Int J Behav Med.* 2013;20:385–96.
235. Gaylord SA, Palsson OS, Garland EL, et al. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. *Am J Gastroenterol.* 2011;106:1678–88.
236. Shaw G, Srivastava ED, Sadlier M, et al. Stress management for irritable bowel syndrome: a controlled trial. *Digestion.* 1991;50:36–42.
237. Craske MG, Wolitzky-Taylor KB, Labus J, et al. A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. *Behav Res Ther.* 2011;49:413–21.
238. Fernandez C, Perez M, Amigo I, et al. Stress and contingency management in the treatment of irritable bowel syndrome. *Stress Med.* 1998;14:31–42.
239. Lackner JM, Jaccard J, Krasner SS, et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. *Clin Gastroenterol Hepatol.* 2008;6:899–906.
240. Jarrett ME, Cain KC, Burr RL, et al. Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions. *Am J Gastroenterol.* 2009;104:3004–14.
241. Boyce PM, Talley NJ, Balaam B, et al. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. *Am J Gastroenterol.* 2003;98:2209–18.
242. Boltin D, Sahar N, Gil E, et al. Gut-directed guided affective imagery as an adjunct to dietary modification in irritable bowel syndrome. *J Health Psychol.* 2015;20:712–20.

243. Thakur ER, Holmes HJ, Lockhart NA, et al. Emotional awareness and expression training improves irritable bowel syndrome: a randomized controlled trial. *Neurogastroenterol Motil.* 2017;29:<https://doi.org/10.1111/nmo.13143>.
244. Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. *Gastroenterology.* 2013;145:1334–46.e1-11.
245. Yang Y, Fang J-Y, Guo X, et al. Efficacy and safety of linaclotide in patients with IBS-C: results from a phase 3, randomized, double-blind, placebo-controlled trial in China and other regions. *Gastroenterology.* 2016;150:S741.
246. Johnston JM, Kurtz CB, MacDougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome and constipation. *Gastroenterology.* 2010;139:1877–86.
247. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. *Am J Gastroenterol.* 2012;107:1702–12.
248. Rao S, Lembo AJ, Shiff SJ, et al. 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. *Am J Gastroenterol.* 2012;107:1714–24.
249. Brenner DM, Fogel R, Dorn SD et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. *Am J Gastroenterol.* 2018;113:735–45.
250. Miner P, De Luca R, La Portilla M, et al. Plecanatide, a novel urogunaylin analog: A 12-week randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). *Am J Gastroenterol.* 2014;109:S541.
251. <https://ir.synergypharma.com/press-releases/detail/1829/synergy-pharmaceuticals-announces-positive-results-in-first>. 2016.
252. <https://ir.synergypharma.com/press-releases/detail/1830/synergy-pharmaceuticals-announces-positive-results-in>. 2016.
253. Shah ED, Kim HM, Schoenfeld P. Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis. *Am J Gastroenterol.* 2018;113:329–38.
254. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. *Aliment Pharmacol Ther.* 2009;29:329–41.
255. Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. *Aliment Pharmacol Ther.* 2008;27:685–96.
256. Cryer B, Drossman DA, Chey WD, et al. Analysis of nausea in clinical studies of lubiprostone for the treatment of constipation disorders. *Dig Dis Sci.* 2017;62:3568–78.
257. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. *N Engl J Med.* 2016;374:242–53.
258. Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. *Gastroenterology.* 2013;145:329–38.e1.
259. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. *Scand J Gastroenterol.* 1987;130:81–84.
260. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome - A double-blind placebo controlled study. *Scand J Gastroenterol.* 1987;130:77–80.
261. Gershon MD. Review article: Serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. *Aliment Pharmacol Ther.* 2004;20:3–14. suppl 7
262. Gershon MD, Tack J. The serotonin signaling system: From basic understanding to drug development for functional GI disorders. *Gastroenterology.* 2007;132:397–414.
263. Miller DP, Alfredson T, Cook SE, et al. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. *Am J Gastroenterol.* 2003;98:1117–22.
264. Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT₃ antagonists and 5-HT₄ agonists in irritable bowel syndrome: systematic review and meta-analysis. *Am J Gastroenterol.* 2009;104:1831–43.
265. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT₃ receptor antagonist. *Aliment Pharmacol Ther.* 1999;13:1149–59.
266. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. *Lancet.* 2000;355:1035–40.
267. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. *Arch Intern Med.* 2001;161:1733–40.
268. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther.* 2000;14:23–34.
269. Lembo T, Wright RA, Lotronex Investigator T, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. *Am J Gastroenterol.* 2001;96:2662–70.
270. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. *Am J Gastroenterol.* 2004;99:2195–203.
271. Chang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. *Am J Gastroenterol.* 2005;100:115–23.
272. Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. *Am J Gastroenterol.* 2007;102:1709–19.
273. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: Systematic review and meta-analysis. *Gut.* 2011;60:209–18.
274. Awad RA, Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. *Colorectal Dis.* 2010;12:1131–8.
275. Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: Macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. *Am J Gastroenterol.* 2013;108:1508–15.
276. Spiller RA, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. *J Neurogastroenterol Motil.* 2012;18:258–68.
277. Bashashati M, Rezaei N, Shafieyoun A, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. *Neurogastroenterol Motil.* 2014;26:1036–48.
278. Martin-Vinas JJ, Quigley EM. Immune response in irritable bowel syndrome: a systematic review of systemic and mucosal inflammatory mediators. *J Dig Dis.* 2016;17:572–81.
279. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. *Am J Gastroenterol.* 2011;106:617–29.
280. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. *Am J Gastroenterol.* 2011;106:601–16.
281. Barbara G, Cremon C, Annesse V, et al. Randomised controlled trial of mesalazine in IBS. *Gut.* 2016;65:82–90.
282. Lam C, Tan W, Leighton M, et al. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). *Gut.* 2016;65:91–9.
283. Aron J, Lin M, Yu J, et al. Mesalamine granules 1500 mg once daily for 12 weeks provides adequate relief of IBS symptoms in irritable bowel syndrome with diarrhea: results from a phase 2 trial. *Am J Gastroenterol.* 2012;107:S711–S712.